ZA200200692B - An improved amorphous form of cefpodoxime proxetil. - Google Patents

An improved amorphous form of cefpodoxime proxetil. Download PDF

Info

Publication number: ZA200200692B
Authority: ZA; South Africa
Prior art keywords: cefpodoxime proxetil; amorphous form; solvent; prepared; mixtures
Prior art date: 1999-07-30

Application number

ZA200200692A

Other languages

English (en)

Inventor

Yatendra Kumar

Arora Rakesh Kumar

Kaptan Singh

Original Assignee

Ranbaxy Lab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-30

Filing date

2002-01-25

Publication date

2003-05-28

2002-01-25 Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd

2003-05-28 Publication of ZA200200692B publication Critical patent/ZA200200692B/en

Links

LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 title claims description 33
229960004797 cefpodoxime proxetil Drugs 0.000 title claims description 33
238000000034 method Methods 0.000 claims description 23
239000002904 solvent Substances 0.000 claims description 22
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
238000004090 dissolution Methods 0.000 claims description 8
-1 chioroform Chemical compound 0.000 claims description 7
238000001694 spray drying Methods 0.000 claims description 7
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
238000001556 precipitation Methods 0.000 claims description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 3
150000002170 ethers Chemical class 0.000 claims description 3
150000002576 ketones Chemical class 0.000 claims description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
229940093499 ethyl acetate Drugs 0.000 claims 2
235000019439 ethyl acetate Nutrition 0.000 claims 2
239000003814 drug Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 3
238000002329 infrared spectrum Methods 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000000634 powder X-ray diffraction Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
JHBWYQRKOUBPCA-UHFFFAOYSA-N 1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Chemical compound S1C2=CC(OC)=CC=C2N=C1NC(=O)NC1=CC=CC=C1 JHBWYQRKOUBPCA-UHFFFAOYSA-N 0.000 description 1
GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
240000005589 Calophyllum inophyllum Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
244000309464 bull Species 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
229960005090 cefpodoxime Drugs 0.000 description 1
WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
229950008364 frentizole Drugs 0.000 description 1
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
229960003660 sertraline hydrochloride Drugs 0.000 description 1
238000005507 spraying Methods 0.000 description 1
JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
229960001544 sulfathiazole Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

ZA200200692A 1999-07-30 2002-01-25 An improved amorphous form of cefpodoxime proxetil. ZA200200692B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IN1036DE1999 IN191496B (ko)	1999-07-30	1999-07-30

Publications (1)

Publication Number	Publication Date
ZA200200692B true ZA200200692B (en)	2003-05-28

Family

ID=11092065

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200200692A ZA200200692B (en)	1999-07-30	2002-01-25	An improved amorphous form of cefpodoxime proxetil.

Country Status (9)

Country	Link
US (1)	US6602999B1 (ko)
EP (1)	EP1204667A4 (ko)
JP (1)	JP2003506329A (ko)
CN (1)	CN1371381A (ko)
AU (1)	AU5839100A (ko)
BR (1)	BR0012865A (ko)
IN (1)	IN191496B (ko)
WO (1)	WO2001009143A1 (ko)
ZA (1)	ZA200200692B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT408226B (de) *	1999-05-05	2001-09-25	Biochemie Gmbh	Kristalliner 7-(2-(2-formylaminothiazol-4-yl)-2
US7045618B2 (en)	2001-02-27	2006-05-16	Ranbaxy Laboratories Limited	Cefpodixime proxetil
US20060106230A1 (en) *	2004-10-18	2006-05-18	Michael Pinchasov	Processes for preparing amorphous atorvastatin hemi-calcium
EA200702518A1 (ru) *	2005-05-16	2008-04-28	Элан Фарма Интернэшнл Лимитед	Композиции на основе наночастиц и с контролируемым высвобождением, включающие цефалоспорин
KR100840132B1 (ko) *	2007-04-17	2008-06-23	재단법인서울대학교산학협력재단	포화 액체 이산화탄소를 사용한 세포독심 프록세틸의 건조
EP2895464A4 (en) *	2012-09-11	2016-06-15	Reddys Lab Ltd Dr	POLYMORPHIC ENZALUTAMIDE FORMS AND THEIR PREPARATION
KR102225416B1 (ko) *	2012-09-11	2021-03-09	메디베이션 프로스테이트 테라퓨틱스 엘엘씨	엔잘루타마이드 제제
WO2017046756A1 (en) *	2015-09-18	2017-03-23	Lupin Limited	Proxetil and axetil esters of cefixime
JP2019520321A (ja) *	2016-05-09	2019-07-18	アナコールファーマシューティカルズ，インコーポレイテッド	フリー体のクリサボロールの結晶形ならびにそれらの調製方法および使用
US11447506B2 (en)	2016-05-09	2022-09-20	Anacor Pharmaceuticals, Inc.	Crystal forms of crisaborole in free form and preparation method and use thereof
US10118932B2 (en) *	2016-06-16	2018-11-06	Xenon Pharmaceuticals Inc.	Solid state forms of spiro-oxindole compounds
EP3510021A1 (en) *	2016-09-06	2019-07-17	Indena S.p.A.	Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same
US10336679B2 (en) *	2016-10-24	2019-07-02	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en)	2016-10-24	2022-06-28	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
CN110248951B (zh) *	2017-02-01	2022-10-28	阿堤亚制药公司	用于治疗丙型肝炎病毒的核苷酸半硫酸盐
JP7365904B2 (ja) *	2017-03-30	2023-10-20	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	（ｓ）－［２－クロロ－４－フルオロ－５－（７－モルホリン－４－イルキナゾリン－４－イル）フェニル］－（６－メトキシ－ピリダジン－３－イル）メタノールの固体形態
IL305343A (en) *	2017-11-22	2023-10-01	Agios Pharmaceuticals Inc	Crystal forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
MX2020010437A (es) *	2018-04-05	2021-01-29	Sumitomo Pharma Oncology Inc	Inhibidores de axl cinasa y uso de los mismos.
KR20200140865A (ko)	2018-04-10	2020-12-16	아테아 파마슈티컬즈, 인크.	간경변증을 갖는 hcv 감염 환자의 치료
CN110251467A (zh) *	2019-06-26	2019-09-20	北京济美堂医药研究有限公司	一种无定形态头孢妥仑匹酯组合物的制备方法
CN110437259B (zh) *	2019-08-14	2021-12-07	中国药科大学	头孢泊肟酯柚皮素共无定形物及其制备方法
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
WO2022176017A1 (ja) *	2021-02-16	2022-08-25	大塚製薬株式会社	非晶質体及び当該非晶質体を含む組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4223153A (en)	1979-02-09	1980-09-16	Eli Lilly And Company	Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea
IT1165253B (it)	1979-07-12	1987-04-22	Blasinachim Spa	Procedimento di fabbricazione di acido chenodesossicolico cristallino puro
US4486425A (en) *	1980-09-30	1984-12-04	Sankyo Company Limited	7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
YU44680B (en) *	1982-07-30	1990-12-31	Glaxo Lab Ltd	Process for obtaining very pure amorphous form of cephuroxim axetile
IL100091A (en)	1990-12-12	1998-08-16	Zeneca Ltd	Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
ES2215161T3 (es) *	1991-09-07	2004-10-01	Aventis Pharma Deutschland Gmbh	Diastereoisomero del ester 1-(isopropoxicarboniloxi)-etilico del acido 3-cefem-4-carboxilico y procedimiento para su preparacion.
US5248699A (en)	1992-08-13	1993-09-28	Pfizer Inc.	Sertraline polymorph
AT413383B (de) *	1998-01-09	2006-02-15	Sandoz Ag	Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil
KR100342943B1 (ko)	1999-08-04	2002-07-02	민경윤	비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

1999
- 1999-07-30 IN IN1036DE1999 patent/IN191496B/en unknown
2000
- 2000-07-24 EP EP00944159A patent/EP1204667A4/en not_active Withdrawn
- 2000-07-24 AU AU58391/00A patent/AU5839100A/en not_active Abandoned
- 2000-07-24 CN CN00812246A patent/CN1371381A/zh active Pending
- 2000-07-24 US US10/048,354 patent/US6602999B1/en not_active Expired - Fee Related
- 2000-07-24 WO PCT/IB2000/001024 patent/WO2001009143A1/en not_active Application Discontinuation
- 2000-07-24 BR BR0012865-1A patent/BR0012865A/pt not_active Application Discontinuation
- 2000-07-24 JP JP2001513950A patent/JP2003506329A/ja active Pending
2002
- 2002-01-25 ZA ZA200200692A patent/ZA200200692B/en unknown

Also Published As

Publication number	Publication date
IN191496B (ko)	2003-12-06
US6602999B1 (en)	2003-08-05
BR0012865A (pt)	2002-07-09
JP2003506329A (ja)	2003-02-18
EP1204667A4 (en)	2002-10-30
AU5839100A (en)	2001-02-19
WO2001009143A1 (en)	2001-02-08
CN1371381A (zh)	2002-09-25
EP1204667A1 (en)	2002-05-15

Publication	Publication Date	Title
ZA200200692B (en)	2003-05-28	An improved amorphous form of cefpodoxime proxetil.
WO2006024900A1 (en)	2006-03-09	Highly pure cefditoren pivoxil
EP1619198B1 (en)	2009-10-14	Process for the preparation of amorphous cefuroxime axetil
US20220380304A1 (en)	2022-12-01	Novel method for producing peramivir trihydrate, and water-based drying thereof
US6833452B2 (en)	2004-12-21	Process for the preparation of highly pure crystalline (R,S)—cefuroxime axetil
CN103874692A (zh)	2014-06-18	卡巴他赛的无定形形式和用于其制备的方法
MXPA03003483A (es)	2003-07-14	Procedimiento para la preparacion de acilfenilalaninas.
EP1689755A2 (en)	2006-08-16	Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin
EP1185266A1 (en)	2002-03-13	Amorphous form of fexofenadine hydrochloride
WO2018029699A1 (en)	2018-02-15	Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof
CN116120393A (zh)	2023-05-16	一种氧化型谷胱甘肽及其晶型和杂质的制备方法
US6458558B1 (en)	2002-10-01	Process for the preparation of β-lactam derivatives
CN112458141A (zh)	2021-03-09	一种3-羟甲基头孢噻肟的制备方法
WO2001079208A1 (fr)	2001-10-25	Nouveau derive d'azetidine et procede de preparation de celui-ci
US6858414B2 (en)	2005-02-22	Multistage process for the preparation of highly pure deferoxamine mesylate salt
WO2008092306A1 (fr)	2008-08-07	Procédé d'hémisynthèse de taxol et de docétaxel
EP1590353B1 (en)	2007-10-10	A process for the preparation of cefpodoxime proxetil
CN108640912A (zh)	2018-10-12	一种匹多莫德的工业化规模制备方法
JP2002205994A (ja)	2002-07-23	セフジトレンピボキシル有機酸塩、無機酸塩、及びその製造方法
WO2021117062A1 (en)	2021-06-17	Process for the preparation of 4-[7-(6-Cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7- diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide and its polymorphs
WO2000077017A1 (en)	2000-12-21	Novel amorphous form of clarithromycin
WO2022215083A1 (en)	2022-10-13	Solid state forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl) carbamate or salts and process for its preparation thereof
CN116731040A (zh)	2023-09-12	一种头孢泊肟酯n-甲酰异丙酯异构体的制备方法
WO2011124992A1 (en)	2011-10-13	Substantially pure strontium ranelate
CA2380183A1 (en)	2001-02-01	A process for the synthesis of beta-lactam derivatives